Your browser doesn't support javascript.
loading
Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease.
Kappelman, Michael D; Adimadhyam, Sruthi; Hou, Laura; Wolfe, Audrey E; Smith, Samantha; Simon, Andrew L; Moyneur, Érick; Reynolds, Juliane S; Toh, Sengwee; Dobes, Angela; Parlett, Lauren E; Haynes, Kevin; Selvan, Mano; Ma, Qianli; Nair, Vinit; Burris, Jessica; Dorand, Jennifer E; Dawwas, Ghadeer K; Lewis, James D; Long, Millie D.
Afiliação
  • Kappelman MD; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Adimadhyam S; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Hou L; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Wolfe AE; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Smith S; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Simon AL; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Moyneur É; StatLog Econometrics Inc, Montreal, Canada.
  • Reynolds JS; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Toh S; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Dobes A; Crohn's & Colitis Foundation, New York, New York, USA.
  • Parlett LE; HealthCore, Wilmington, Delaware, USA.
  • Haynes K; HealthCore, Wilmington, Delaware, USA.
  • Selvan M; Humana Healthcare Research, Louisville, Kentucky, USA.
  • Ma Q; Humana Healthcare Research, Louisville, Kentucky, USA.
  • Nair V; Humana Healthcare Research, Louisville, Kentucky, USA.
  • Burris J; Yale University School of Medicine, New Haven, Connecticut, USA.
  • Dorand JE; Crohn's & Colitis Foundation, New York, New York, USA.
  • Dawwas GK; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Lewis JD; Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Long MD; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Am J Gastroenterol ; 118(4): 674-684, 2023 04 01.
Article em En | MEDLINE | ID: mdl-36508681
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Crohn / Ustekinumab Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Gastroenterol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Crohn / Ustekinumab Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Gastroenterol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos